HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Genmab (NASDAQ:GMAB) and maintained a price target of $51.
October 18, 2023 | 10:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $51.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $51 indicates the firm's continued confidence in the stock's potential, which could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100